Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways
Benzinga Insights 8 months ago
Earnings
Protagonist Therapeutics (NASDAQ:PTGX) reported its Q4 earnings results on Wednesday, February 25, 2026 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Protagonist Therapeutics missed estimated earnings by -27.78%, reporting an EPS of $-0.69 versus an estimate of $-0.54.
Revenue was down $163.20 million from the same period last year.
Overview of Past Earnings
In the previous quarter, the company missed on EPS by $0.0, resulting in a 0.3% drop change in the share price the following day.
Here's a look at Protagonist Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.62 | -0.53 | 0.11 | 1.03 |
| EPS Actual | -0.62 | -0.55 | -0.19 | 1.98 |
| Revenue Estimate | 6.48M | 9.15M | 30.44M | 53.52M |
| Revenue Actual | 4.71M | 5.55M | 28.32M | 170.64M |
To track all earnings releases for Protagonist Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.